debt_leverage_profile
Minimal long-term debt; primarily equity-financed clinical-stage biotech; 20% rate rise immaterial to interest expense
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; negligible floating-rate debt; primary cash burn funded by equity raises, not credit facilities
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API synthesis reliance on Indian/Chinese CMOs; key chokepoints are India pharma API corridor and China chemical precursor exports
Inferred
Agent_Inference
international_expansion_readiness
Minimal international commercial revenue; no material sovereign currency devaluation exposure in top markets currently
Inferred
Agent_Inference
geographic_footprint
Predominantly US-based revenue and operations; negligible forex translation risk from international markets at current stage
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-source CMO dependency likely exceeds 30% of production input cost; non-substitutable on short notice for sabizabulin API
Inferred
Agent_Inference
business_model_type_primary
Drug development/commercialization; not cloud-dependent for core operations; cloud termination would disrupt data/IT, not core product
Inferred
Agent_Inference
business_model_type_secondary
Clinical-stage pharmaceutical; secondary revenue from FC2 female condom commercial product sales
Inferred
Agent_Inference
switching_cost_profile
Minimal API coupling risk; internal R&D systems; clinical data platforms (Veeva/Medidata) are industry-standard with moderate switching cost
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue from FDA-regulated drug sales and contraceptive products; not a passive investment scheme
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR/CCPA exposure from clinical trial patient data across EU sites; requires DPA agreements and data transfer compliance
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; small-cap niche oncology/contraceptive company with minimal market share; no dominant market position
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Primarily transactional; FC2 condom product sales ~100% transactional; no recurring subscription revenue stream identified
Inferred
Agent_Inference
monetization_vector
Product sales (FC2 condoms to governments/NGOs) and future oncology drug licensing/sales; grant funding supplemental
Inferred
Agent_Inference
pricing_architecture
FC2 pricing vulnerable to government procurement budget cuts; oncology drug pricing dependent on formulary access and PBM negotiations
Inferred
Agent_Inference
pricing_power_rating
Weak to moderate; FC2 subject to government tender pricing pressure; sabizabulin pricing power contingent on FDA approval and competitive landscape
Inferred
Agent_Inference
target_gross_margin_bracket
34.7% Gross Margin (Moderate (20-40%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; physical product and prescription drug model; no digital free-tier leakage
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is headcount-sublinear post-approval; commercialization scales with small salesforce; clinical phase is headcount-intensive
Inferred
Agent_Inference
marginal_cost_of_growth
Post-approval marginal cost driven by COGS and manufacturing scale, not proportional headcount; favorable unit economics potential
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; direct sales and government procurement model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, oncology drug CAC requires expanded oncologist detailing; FC2 relies on large government/NGO contracts with high fixed-cost bids
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; pharmaceutical products have no user-base interdependency; value is clinical, not network-driven
Inferred
Agent_Inference
asset_efficiency_ratio
-310.4% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; FC2 demand tied to global health funding (recession-sensitive); oncology drugs historically recession-resistant
Inferred
Agent_Inference
customer_segment_primary
Government health agencies and NGOs (FC2 condom buyers); high concentration risk—USAID/UNFPA represent significant FC2 revenue
Inferred
Agent_Inference
customer_segment_secondary
Oncology patients and hospital/clinic systems (future sabizabulin market); diversified but currently pre-revenue in this segment
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0000863894
High
SEC-EDGAR
ticker
VERU
High
SEC-EDGAR